S
PSTX

SignatureFD’s Poseida Therapeutics, Inc. Common Stock PSTX Stock Holding History

SignatureFD’s Portfolio PSTX Stock Details PSTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-211
Closed -$1.12K – 3400
2022
Q4 		$1.12K Buy
+211
New +$965 ﹤0.01% 2951
2021
Q4 		– Sell
-98
Closed -$1K – 3304
2021
Q3 		$1K Buy
+98
New +$841 ﹤0.01% 2961

Other funds holding PSTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

SignatureFD's PSTX Position: Q1 2023 in Review

SignatureFD sold out of Poseida Therapeutics, Inc. Common Stock (PSTX) in Q1 2023, closing a stake of 211 shares — an estimated $1.12K sold.

SignatureFD first reported a position in PSTX in Q3 2021 and held it in 2 quarters. The position peaked at $1.12K in Q4 2022. 101 funds tracked by Wall St. Rank hold PSTX as of Q1 2023.

  • SignatureFD reported no remaining Poseida Therapeutics, Inc. Common Stock position as of Q1 2023 after selling out during the quarter.
  • SignatureFD sold 211 Poseida Therapeutics, Inc. Common Stock shares in Q1 2023, an estimated $1.12K.
  • SignatureFD first reported a position in Poseida Therapeutics, Inc. Common Stock in Q3 2021 and held it in 2 quarters.
  • SignatureFD's Poseida Therapeutics, Inc. Common Stock position peaked at $1.12K in Q4 2022.
  • 101 funds tracked by Wall St. Rank held Poseida Therapeutics, Inc. Common Stock as of Q1 2023.

Based on SignatureFD's 13F filing for Q1 2023, filed 28 Apr 2023.